Autus Asset Management LLC raised its holdings in Abbott Laboratories (NYSE:ABT) by 0.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 124,148 shares of the healthcare product maker’s stock after purchasing an additional 752 shares during the period. Autus Asset Management LLC’s holdings in Abbott Laboratories were worth $6,035,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ABT. MUFG Americas Holdings Corp lifted its holdings in shares of Abbott Laboratories by 20.1% in the first quarter. MUFG Americas Holdings Corp now owns 325,762 shares of the healthcare product maker’s stock valued at $14,467,000 after purchasing an additional 54,609 shares in the last quarter. Dumont & Blake Investment Advisors LLC raised its position in shares of Abbott Laboratories by 1.7% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 18,780 shares of the healthcare product maker’s stock valued at $834,000 after buying an additional 305 shares during the last quarter. LS Investment Advisors LLC raised its position in shares of Abbott Laboratories by 27.1% in the first quarter. LS Investment Advisors LLC now owns 134,740 shares of the healthcare product maker’s stock valued at $5,984,000 after buying an additional 28,762 shares during the last quarter. American Assets Investment Management LLC raised its position in shares of Abbott Laboratories by 58.8% in the first quarter. American Assets Investment Management LLC now owns 40,500 shares of the healthcare product maker’s stock valued at $1,799,000 after buying an additional 15,000 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Abbott Laboratories by 21.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 566,917 shares of the healthcare product maker’s stock valued at $25,177,000 after buying an additional 100,886 shares during the last quarter. 69.99% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/autus-asset-management-llc-acquires-752-shares-of-abbott-laboratories-abt/1723160.html.

Shares of Abbott Laboratories (NYSE:ABT) opened at $55.80 on Friday. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $56.69. The stock has a market cap of $97,125.53, a price-to-earnings ratio of 23.15, a PEG ratio of 2.09 and a beta of 1.06. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.01. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The company had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. During the same quarter in the prior year, the business earned $0.59 earnings per share. The business’s quarterly revenue was up 28.8% compared to the same quarter last year. research analysts forecast that Abbott Laboratories will post 2.49 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were given a $0.265 dividend. This represents a $1.06 annualized dividend and a dividend yield of 1.90%. The ex-dividend date was Thursday, October 12th. Abbott Laboratories’s payout ratio is currently 83.47%.

In other news, insider Alejandro D. Wellisch sold 2,153 shares of the company’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $55.86, for a total value of $120,266.58. Following the completion of the transaction, the insider now directly owns 10,256 shares in the company, valued at $572,900.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the company’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $56.21, for a total transaction of $5,430,054.63. Following the completion of the transaction, the executive vice president now owns 142,082 shares of the company’s stock, valued at $7,986,429.22. The disclosure for this sale can be found here. Insiders sold 308,939 shares of company stock valued at $16,835,789 in the last three months. Company insiders own 0.76% of the company’s stock.

A number of equities analysts have recently weighed in on the stock. Citigroup Inc. assumed coverage on shares of Abbott Laboratories in a research report on Thursday, August 17th. They issued a “neutral” rating and a $53.00 price objective for the company. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research report on Friday, September 22nd. Barclays PLC boosted their price objective on shares of Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research report on Thursday, September 28th. J P Morgan Chase & Co assumed coverage on shares of Abbott Laboratories in a research report on Friday, October 6th. They issued a “neutral” rating and a $60.00 price objective for the company. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $65.00 price objective on shares of Abbott Laboratories in a research report on Thursday, October 19th. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Abbott Laboratories currently has a consensus rating of “Buy” and an average target price of $56.81.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.